Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 22.1% in February

Carisma Therapeutics, Inc. (NASDAQ:CARM) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 464,400 shares, a decrease of 22.1% from the February 13th total of 596,500 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average daily volume of 361,600 shares, the short-interest ratio is currently 1.3 days.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CARM shares. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Evercore ISI reiterated an “in-line” rating and issued a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. D. Boral Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Carisma Therapeutics in a report on Monday, January 13th. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Five research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.94.

Carisma Therapeutics Stock Up 3.8 %

NASDAQ:CARM traded up $0.02 during mid-day trading on Wednesday, reaching $0.42. The stock had a trading volume of 394,182 shares, compared to its average volume of 371,954. The business’s 50 day moving average is $0.45 and its 200 day moving average is $0.70. Carisma Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.66. The stock has a market cap of $17.37 million, a P/E ratio of -0.27 and a beta of 1.55. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Hedge Funds Weigh In On Carisma Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wexford Capital LP grew its holdings in Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after purchasing an additional 24,600 shares during the last quarter. Finally, Barclays PLC grew its holdings in Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.